Cerus Corporation Reports Strong Revenue Growth in Q3

image

Cerus Corporation Reports Strong Revenue Growth in Q3

Biomedical products company Cerus Corporation (CERS) announced that in the third quarter of 2024, product revenues reached $46 million, reflecting a 16% increase, while total revenues for the first nine months amounted to $129.5 million, an 18% year-over-year increase. The primary driver of the company’s growth was its North America platelet business, which experienced a 17% increase, particularly in the United States.

Cerus also raised its full-year product revenue guidance, citing positive trends in the INTERCEPT Fibrinogen Complex (IFC) business and increased production capacity. Additionally, the company highlighted the $248 million contract with BARDA aimed at advancing the INTERCEPT Red Blood Cell (RBC) program, which addresses public health concerns related to blood supply safety.

Key Points:

  • Third-quarter product revenues reached $46 million, up 16% year-over-year.
  • Full-year product revenue guidance was raised to $177-179 million.
  • Gross profit for the third quarter was $26.2 million, with margins increasing to 56.9%.
  • Operating expenses decreased by 8% to $31.8 million.
  • Positive operating cash flow of $4.1 million was recorded, showing significant improvement compared to last year.
  • The company plans to launch its LED illuminator in Europe in 2025 and in the US in 2026.
  • New customer acquisitions and deeper penetration in existing accounts are expected to sustain growth.

Company Outlook:

  • Full-year revenue guidance for 2024 has been raised to between $177 million and $179 million.
  • For the year, IFC revenue is projected to be between $9 million and $10 million.
  • The LED illuminator launch is slated for 2025 in Europe and in 2026 in the US.
  • Continuous growth is expected from new customer acquisitions and increased usage among existing customers.

Downside Highlights:

  • The company is taking a conservative stance on its full-year guidance due to operational uncertainties.
  • High costs associated with the new LED illuminator may not significantly improve gross margins.

Upside Highlights:

  • Strong growth in North America platelet sales, particularly a 17% increase in the US.
  • Positive trends in the IFC business and increased supply capacity led to the upward revision of revenue guidance.
  • The $248 million BARDA contract supports the INTERCEPT RBC program and addresses emerging public health concerns.

Shortcomings:

  • No specific revenue guidance was provided for 2025.
  • Reduced state contract revenues in the third quarter due to the completion of work under a 2016 contract.

Q&A Highlights: CEO Obi Greenman discussed the company's significant intellectual property developments over the last five years. CFO Kevin Green provided insights on the company's financial trajectory, including expectations for positive adjusted EBITDA and improved cash flow. COO Vivek Jayaraman summarized strategic initiatives such as regulatory submissions and international market expansion.

Cerus Corporation ended the third quarter with $75.6 million in cash and cash equivalents, generating positive operating cash flows, indicating significant improvement compared to last year. The company's executives expressed cautious optimism about future growth and cash flow sustainability while maintaining conservative forecasts.

Furthermore, they underscored the importance of government contracts, like the BARDA contract, in supporting R&D expenditures and advancing the company’s product pipeline. Cerus aims to focus on customer acquisition and usage expansion, targeting a quarterly run rate of $3 million to $4 million for IFC by the end of the year.

With plans to participate in upcoming investor conferences, Cerus Corporation remains committed to enhancing shareholder value through strategic growth and operational efficiency.

InvestingPro Insights: Cerus Corporation's (CERS) recent financial performance aligns with several key metrics and insights from InvestingPro. The company’s 16% increase in product revenues to $46 million in the third quarter positively impacts its growth trajectory. According to InvestingPro data, a robust 10.79% revenue growth was observed over the last twelve months as of Q2 2024. This growth trend is also supported by a 16.02% quarterly revenue increase during Q2 2024, indicating consistent expansion.

The company’s gross profit margin of 55.13% for the last twelve months closely aligns with the reported 56.9% margin in the third quarter, demonstrating Cerus's ability to maintain healthy margins. However, it is important to note that despite revenue growth and margin improvements, Cerus is not yet profitable, as reflected in an InvestingPro Tip stating that analysts do not expect the company to be profitable this year.

Another relevant InvestingPro Tip emphasizes that Cerus operates with a moderate level of debt, which can be viewed positively, especially considering the company’s recent $4.1 million positive operating cash flow. This moderate debt level may provide Cerus with financial flexibility to invest in growth initiatives, such as the LED illuminator launch and expansion of the INTERCEPT product line.

For investors seeking a more comprehensive analysis, InvestingPro offers additional insights and recommendations. Currently, there are six further InvestingPro Tips available for Cerus Corporation, providing valuable context to understand the company's financial health and market position.